• No results found

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

N/A
N/A
Protected

Academic year: 2021

Share "Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis"

Copied!
17
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Figure 1. Numbers of Patients Who Underwent Randomization and Who Completed Treatment.
Table 1. Baseline Characteristics of the Patients. Characteristic Placebo (N = 92) Fingolimod, 1.25 mg (N = 93) Fingolimod, 5.0 mg (N = 92) Intention-to-treat population Age — yr Mean 37.1 38.0 38.3 Range 19–56 19–60 18–59 Age — no
Table 2. MRI and Clinical End Points at 6 Months in the Core Study.
Figure 2. Proportions of Patients Who Were Free of Gadolinium-Enhanced  Lesions on T 1 -Weighted MRI at 0 to 6 Months (Panel A) and the Estimated  Time to a First Confirmed Relapse (Panel B).
+4

References

Related documents

Prepared by: Center for Public Affairs Research, University of Nebraska at Omaha, January 2014 *Income for the past 12 months (in 2012 inflation-adjusted dollars)... Census

The treatments were plowing with local maresha (control), mouldboard, mouldboard plow and tied with tie-ridger, local maresha and tied with tie-ridger.. Cost

 Considering that none of the towns in the north have established preparation and processing center or fixed BSC. Therefore, building fixed BSC in Marand can reduce the

The MMDS is divided into three functional parts: coding of medical causes of death reported by the physician (MICAR), selection of the underlying cause of death (ACME) and

The Limits to Growth generic archetype was chosen as the archetype for the theory building process because the research focus of this study is concerned with the issue of

We performed virtual screening of the complete Human Metabolite Database (HMDB) for docking to the multiple sclerosis (MS) susceptible DRB1*15:01 allele and compared the results

The term ‘‘lymphedema’’ has historically been defined as edema, which develops as a result of failure of lymphatic drainage either through problems in lymphatic development